These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 20404484)

  • 1. A growing family: adding mutated Erbb4 as a novel cancer target.
    Rudloff U; Samuels Y
    Cell Cycle; 2010 Apr; 9(8):1487-503. PubMed ID: 20404484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
    Roskoski R
    Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ERBB4 mutation analysis: emerging molecular target for melanoma treatment.
    Lau C; Killian KJ; Samuels Y; Rudloff U
    Methods Mol Biol; 2014; 1102():461-80. PubMed ID: 24258993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The ErbB/HER family of protein-tyrosine kinases and cancer.
    Roskoski R
    Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4.
    Prickett TD; Agrawal NS; Wei X; Yates KE; Lin JC; Wunderlich JR; Cronin JC; Cruz P; Rosenberg SA; Samuels Y
    Nat Genet; 2009 Oct; 41(10):1127-32. PubMed ID: 19718025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Developments for Personalized Medicine of Lung Cancer Subtypes: Mass Spectrometry-Based Clinical Proteogenomic Analysis of Oncogenic Mutations.
    Nishimura T; Nakamura H
    Adv Exp Med Biol; 2016; 926():115-137. PubMed ID: 27686809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ErbB Receptors and Cancer.
    Wang Z
    Methods Mol Biol; 2017; 1652():3-35. PubMed ID: 28791631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic targeting of the epidermal growth factor receptor in human cancer.
    Dhomen NS; Mariadason J; Tebbutt N; Scott AM
    Crit Rev Oncog; 2012; 17(1):31-50. PubMed ID: 22471663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ERBB1/2/3 Expression, Prognosis, and Immune Infiltration in Cutaneous Melanoma.
    Liu S; Geng R; Lin E; Zhao P; Chen Y
    Front Genet; 2021; 12():602160. PubMed ID: 33732282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Irreversible multitargeted ErbB family inhibitors for therapy of lung and breast cancer.
    Subramaniam D; He AR; Hwang J; Deeken J; Pishvaian M; Hartley ML; Marshall JL
    Curr Cancer Drug Targets; 2015; 14(9):775-93. PubMed ID: 25435079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Somatic mutations of the ERBB4 kinase domain in human cancers.
    Soung YH; Lee JW; Kim SY; Wang YP; Jo KH; Moon SW; Park WS; Nam SW; Lee JY; Yoo NJ; Lee SH
    Int J Cancer; 2006 Mar; 118(6):1426-9. PubMed ID: 16187281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The absence of the ERBB4 hotspot mutations in melanomas in patients from southern China.
    Zhou QM; Li W; Guan YX; Zhang X; Chen XC; Ding Y; Wen XZ; Peng RQ; Yan SM; Zhang XS
    Chin J Cancer; 2013 Jul; 32(7):410-4. PubMed ID: 23237222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.
    Uribe P; Gonzalez S
    Pathol Res Pract; 2011 Jun; 207(6):337-42. PubMed ID: 21531084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting of ErbB1, ErbB2, and their Dual Targeting Using Small Molecules and Natural Peptides: Blocking EGFR Cell Signaling Pathways in Cancer: A Mini-Review.
    Patnaik SK; Chandrasekar MJN; Nagarjuna P; Ramamurthi D; Swaroop AK
    Mini Rev Med Chem; 2022 Oct; 22(22):2831-2846. PubMed ID: 35549881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ErbB2 and ErbB3 do not quantitatively modulate ligand-induced ErbB4 tyrosine phosphorylation.
    Feroz K; Williams E; Riese DJ
    Cell Signal; 2002 Sep; 14(9):793-8. PubMed ID: 12034361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of ErbB4 in breast cancer.
    Sundvall M; Iljin K; Kilpinen S; Sara H; Kallioniemi OP; Elenius K
    J Mammary Gland Biol Neoplasia; 2008 Jun; 13(2):259-68. PubMed ID: 18454307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidermal growth factor receptor dependence in human tumors: more than just expression?
    Arteaga CL
    Oncologist; 2002; 7 Suppl 4():31-9. PubMed ID: 12202786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting ErbB receptors in high-grade glioma.
    Berezowska S; Schlegel J
    Curr Pharm Des; 2011; 17(23):2468-87. PubMed ID: 21827413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Q43L mutant of neuregulin 2β is a pan-ErbB receptor antagonist.
    Wilson KJ; Mill CP; Gallo RM; Cameron EM; VanBrocklin H; Settleman J; Riese DJ
    Biochem J; 2012 Apr; 443(1):133-44. PubMed ID: 22216880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in molecular-based personalized non-small-cell lung cancer therapy: targeting epidermal growth factor receptor and mechanisms of resistance.
    Jotte RM; Spigel DR
    Cancer Med; 2015 Nov; 4(11):1621-32. PubMed ID: 26310719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.